Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/irbesartan-Gx0JuqqJ7n
References (115)
-
C. Richer, P. Fornés, C. Cazaubon, V. Domergue, D. Nisato, J. Giudicelli (1999)
Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.Cardiovascular research, 41 1
-
T. Tadano, N. Takahashi, O. Nakagawasai, K. Tan-No, S. Kaneko, K. Matsunaga, Y. Ohizumi, K. Kisara (1998)
Central action of 9-methyl-7-bromoeudistomin D (MBED), a derivative of eudistomin D isolated from Eudistoma olivaceum.Methods and findings in experimental and clinical pharmacology, 20 1
-
(1998)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38BMJ, 317
-
E Feraco (1999)
Therapeutic effects of irbesartan in left ventricular hypertrophy [abstract no. D019]Am J Hypertens, 12
-
T. Thrasher, C. Shifflett, D. Ramsay (1999)
F002: Blockade of angiotensin type 1 (AT1) receptors reduces ventricular hypertrophy in response to aortic stenosis in rats.American Journal of Hypertension, 12
-
K. Stumpe, D. Haworth, C. Hoglund, L. Kerwin, A. Martin, T. Simon, C. Masson, K. Kassler-Taub, M. Osbakken (1998)
Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.Blood pressure, 7 1
-
J. Rosenstock, L. Rossi, C. Lin, D. MacNeil, M. Osbakken (1998)
The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non‐responsive to hydrochlorothiazide aloneJournal of Clinical Pharmacy and Therapeutics, 23
-
L. Ramsay, B. Williams, G. Johnston, G. Macgregor, L. Poston, J. Potter, N. Poulter, G. Russell, for Society (1999)
Guidelines for management of hypertension: report of the third working party of the British Hypertension SocietyJournal of Human Hypertension, 13
-
N. Vachharajani, W. Shyu, M. Mantha, Jong‐Soon Park, D. Greene, R. Barbhaiya (1998)
Lack of Effect of Food on the Oral Bioavailability of Irbesartan in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 38
-
A. Anderson (1996)
Discordant effects of an angiotensin converting enzyme inhibitor (ACEI) vs an AII receptor antagonist (AA) on blood pressure and renal damage in spontaneously hypertensive rats (SHR).American Journal of Hypertension, 9
-
M. Bourrié, V. Meunier, Y. Berger, G. Fabre (1999)
Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.Drug metabolism and disposition: the biological fate of chemicals, 27 2
-
SJ Kovacs, JH Wilton, RA Blum (1999)
Steady state (SS) pharmacokinetics (PK) of irbesartan alone and in combination with fluconazole (F) [abstract PI-59]Clin Pharmacol Ther, 65
-
G. Belz, R. Butzer, S. Kober, C. Mang, E. Mutschler (1999)
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assayClinical Pharmacology & Therapeutics, 66
-
N. Moreau, C. Richer, M. Vincent, J. Giudicelli (1993)
26 Sympatho-inhibitory effects of SR 47436, a new angiotensin II antagonist, in the pithed spontaneously hypertensive ratJournal of Hypertension, 11
-
M Marino, NN Vachharajani (1998)
The pharmacokinetics of irbesartan are not altered in special populations [abstract no. E023]Am J Hypertens, 11
-
A. Pechère-Bertschi, J. Nussberger, L. Decosterd, Catherine Armagnac, J. Sissmann, M. Bouroudian, H. Brunner, M. Burnier (1998)
Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patientsJournal of Hypertension, 16
-
T. Bunt (1999)
Problems with interpreting the data in Kassler-Taub et al's article comparing irbesartan and losartan.American journal of hypertension, 12 1 Pt 1
-
P. Larochelle, J. Flack, T. Marbury, P. Sareli, E. Krieger, R. Reeves (1997)
Effects and Tolerability of Irbesartan Versus Enalapril in Patients With Severe Hypertension fn1American Journal of Cardiology, 80
-
O. Chung, T. Csikós, T. Unger (1999)
Angiotensin II receptor pharmacology and AT1-receptor blockersJournal of Human Hypertension, 13
-
B. Mangold, W. Gielsdorf, M. Marino (1999)
Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarinEuropean Journal of Clinical Pharmacology, 55
-
L. Hansson, A. Zanchetti, S. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, J. Ménard, K. Rahn, H. Wedel, S. Westerling (1998)
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 351
-
S. Oparil, R. Guthrie, A. Lewin, T. Marbury, K. Reilly, J. Triscari, J. Witcher (1998)
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.Clinical therapeutics, 20 3
-
P. Vanderheyden, F. Fierens, J.-P. Backer, Norbert Fraeyman, G. Vauquelin (1999)
Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO‐K1 cells expressing human angiotensin II AT1 receptorsBritish Journal of Pharmacology, 126
-
T. Simon, R. Gelarden, Steven Freitag, K. Kassler-Taub, R. Davies (1998)
Safety of irbesartan in the treatment of mild to moderate systemic hypertension.The American journal of cardiology, 82 2
-
T. Bunt (1999)
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan.Clinical therapeutics, 21 3
-
Daniel Levy, M. Larson, R. Vasan, W. Kannel (1996)
The progression from hypertension to congestive heart failure.JAMA, 275 20
-
K. Mclaughlin, A. Jardine (1999)
Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: either or both for primary renal disease?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 14 1
-
F. Schmitt, F. Martínez, G. Brillet, T. Nguyen-Khoa, R. Brouard, J. Sissmann, B. Lacour, J. Grunfeld (1998)
Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects.Journal of cardiovascular pharmacology, 31 2
-
R Fogari, L Poletti, A Zoppi (1999)
Effects of celipropol, irbesartan and lisinopril on insulin sensitivity in non diabetic hypertensive patients [abstract no. 36]Cardiovasc Drugs Ther, 13
-
M. Marino, N. Vachharajani (1998)
Pharmacokinetics of Irbesartan Are Not Altered in Special PopulationsJournal of Cardiovascular Pharmacology, 40
-
N Vacharajani, WC Shyu, D Greene (1997)
The effect of age on the pharmacokinetics of irbesartan [abstract]J Clin Pharmacol, 37
-
R. Collins, R. Peto, J. Godwin, S. MacMahon (1990)
Blood pressure and coronary heart diseaseThe Lancet, 336
-
M. Marino, J. Hammett, I. Ferreira, N. Ford, H. Uderman (1998)
Effect of Nifedipine on the Steady-State Pharmacokinetics and Pharmacodynamics of Irbesartan in Healthy SubjectsJournal of Cardiovascular Pharmacology and Therapeutics, 3
-
R. Guthrie, R. Saini, T. Herman, W. Pleskow, D. Sprecher, G. Collins (1998)
Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary HypertensionClinical Drug Investigation, 15
-
S. Sheps (1997)
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.Archives of internal medicine, 157 21
-
V Rizzo, S Villatico Campbell, F Maio (1999)
Cardiac damage and blood pressure variability reduction after antihypertensive drug therapy with irbesartan [abstract no. P.71]J Hum Hypertens, 13
-
ER Havranek (1998)
The effects of the angiotensin II receptor antagonist irbesartan in patients with congestive heart failureCardiovasc Rev Rep, 19
-
HE Bays, JS Park, K Reilly (1999)
Irbesartan safety and effectiveness: a postmarketing surveillance study [abstract]Am J Hypertens, 12
-
R Guthrie, R Saini, T Herman (1998)
Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertensionA double-blind, placebo-controlled, dose-titration study. Clin Drug Invest, 15
-
T. Kahan (1998)
The importance of left ventricular hypertrophy in human hypertension.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 16 7
-
A. Chobanian (1998)
The ASH special lecture comparison of the effects of ACE inhibition and AT1 receptor blockade on atherosclerosisAmerican Journal of Hypertension, 11
-
R. Jackson (1995)
What are the implications for the community of the discrepancy between the theory and practice of BP control?Journal of human hypertension, 9 Suppl 2
-
C. Lacour, F. Canals, C. Cazaubon, D. Nisato (1995)
Central effects of irbesartan, an AT1 antagonist in ratsPharmacological Research, 31
-
C. Polidori, Roberto Ciccocioppo, Dino Nisato, C. Cazaubon, M. Massi (1998)
Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment.European journal of pharmacology, 352 1
-
D. Martineau, N. Yamaguchi, R. Briand (1995)
Inhibition by BMS 186295, a selective nonpeptide AT1 antagonist, of adrenal catecholamine release induced by angiotensin II in the dog in vivo.Canadian journal of physiology and pharmacology, 73 4
-
MahendrS. Kochar, R. Guthrie, J. Triscari, K. Kassler-Taub, R. Reeves (1999)
Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.American journal of hypertension, 12 8 Pt 1
-
M. Marino, K. Langenbacher, R. Raymond, N. Ford, K. Lasseter (1998)
Pharmacokinetics and Pharmacodynamics of Irbesartan in Patients with Hepatic CirrhosisThe Journal of Clinical Pharmacology, 38
-
J. Ambrose, D. Pribnow, G. Giraud, K. Perkins, L. Muldoon, B. Greenberg (1999)
Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.Journal of cardiovascular pharmacology, 33 3
-
J. Gillis, A. Markham (1997)
Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.Drugs, 54 6
-
N Vijay, IA Alhaddad, DM Denny (1998)
Irbesartan compared with lisinopril in patients with mild to moderate heart failure [abstractno. 812-2]J Am Coll Cardiol, 31
-
JG Porush, LG Hunsicker, WR Clark (1999)
Multi-center collaborative trial of angiotensin II receptor antagonism on renal function, morbidity and mortality in hypertensive type II diabetic patients with nephropathy [abstract no. P.22]J Hum Hypertens, 13
-
T. Littlejohn, R. Saini, K. Kassler-Taub, S. Chrysant, T. Marbury (1999)
Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies.Clinical and experimental hypertension, 21 8
-
K Kassler-Taub, T Littlejohn, W Elliott (1998)
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension [published erratum appears in Am J Hypertens 1998 Jun;11 (6 Pt 1):736]Am J Hypertens, 11
-
P. Korner, G. Jennings (1998)
Assessment of prevalence of left ventricular hypertrophy in hypertension.Journal of hypertension, 16 6
-
(2000)
British National Formulary. No.39 -
M. Marino, K. Langenbacher, N. Ford, H. Uderman (1998)
Pharmacokinetics and Pharmacodynamics of Irbesartan in Healthy SubjectsThe Journal of Clinical Pharmacology, 38
-
M Weber, R Saini, K Kassler-Taub (1998)
Irbesartan combined with low-dose hydrochlorothiazide for mild-to-moderate hypertension [abstract no. P16.27]J Hypertens, 16
-
P. Raskin, R. Guthrie, J. Flack, R. Reeves, R. Saini (1999)
The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazideJournal of Human Hypertension, 13
-
J. Herbert, C. Delisée, F. Dol, P. Schaeffer, C. Cazaubon, D. Nisato, P. Chatelain (1994)
Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro.European journal of pharmacology, 251 2-3
-
Edward Havranek, I. Thomas, William Smith, G. Ponce, M. Bilsker, Mark Munger, Robert Wolf (1999)
Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.Journal of the American College of Cardiology, 33 5
-
(1999)
1999 World Health Organization -International Society of Hypertension Guidelines for the Management of HypertensionJ Hypertens, 17
-
F. Spinale, H. Holzgrefe, J. Walker, R. Mukherjee, S. Kribbs, J. Powell, M. Antonaccio (1997)
Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: effects on ventricular and myocyte function.Journal of cardiovascular pharmacology, 30 5
-
S Oparil, R Guthrie, AJ Lewin (1998)
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartanIrbesartan/Losartan Study Investigators. Clin Ther, 20
-
Yoon Cha, V. Pearson (1999)
Angioedema Due to LosartanAnnals of Pharmacotherapy, 33
-
MR Weir, N Tolchin, P Toth (1998)
Addition of hydrochlorothiazide to irbesartan produces further dose-related reductions in blood pressure within two weeks [abstract no. P16.34]J Hypertens, 16
-
L. Mazzolai, M. Maillard, J. Rossat, J. Nussberger, Hans Brunner, M. Burnier (1999)
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.Hypertension, 33 3
-
H. Bays, J. Park, K. Reilly, J. Triscari, AsthmaNet Investigators (1999)
Irbesartan safety and effectiveness: a post-marketing surveillance studyAmerican Journal of Hypertension, 12
-
M. Alderman, K. Arakawa, J. Beilin, J. Chalmers, S. Erdine, M. Fujishima, P. Hamet, L. Hansson, L. Landsberg, F. Leenen, L. Lindholm, Lisheng Liu, A. Mabadeje, S. MacMahon, G. Mancia, I. Martin, A. Mimran, K. Rahn, A. Ribeiro, P. Sleight, J. Whitworth, A. Zanchetti (1999)
1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension endorsed by the Lebanese Hypertension League, 47
-
HS Mackenzie, AP Provoost, JL Troy (1996)
Irbesartan reduces blood pressure and prevents renal injury in fawn-hooded hypertensive rats [abstract no. B5]Am J Hypertens, 9
-
R Fogari, S Ambrosoli, L Corradi (1997)
24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoringJ Hypertens, 15
-
N. Vachharajani, W. Shyu, R. Barbhaiya (1997)
Pharmacokinetic Interaction Between Butorphanol Nasal Spray and Oral Metoclopramide in Healthy WomenThe Journal of Clinical Pharmacology, 37
-
M. Marino, K. Langenbacher, N. Ford, F. Beierle, R. Raymond, E. Shamblen, K. Lasseter (1997)
Effect of Hydrochlorothiazide on the Pharmacokinetics and Pharmacodynamics of the Angiotensin II Blocker IrbesartanClinical Drug Investigation, 14
-
G. Pylypchuk (1998)
ACE Inhibitor—Versus Angiotensin II Blocker–Induced Cough and Angioedema, 32
-
H. Mackenzie (1996)
Irbesartan reduces blood pressure and prevents renal injury in fawn-hooded hypertensive rats.American Journal of Hypertension, 9
-
N. Vachharajani, W. Shyu, T. Chando, D. Everett, D. Greene, R. Barbhaiya (1998)
Oral Bioavailability and Disposition Characteristics of Irbesartan, an Angiotensin Antagonist, in Healthy VolunteersThe Journal of Clinical Pharmacology, 38
-
R Collins, R Peto, J Godwin (1990)
Blood pressure and coronary heart disease [letter]Lancet, 336
-
A. Mimran, L. Ruilope, L. Kerwin, M. Nys, D. Owens, K. Kassler-Taub, M. Osbakken (1998)
A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertensionJournal of Human Hypertension, 12
-
M Cooper, D Anzalone, L Townes (1998)
Safety and efficacy of irbesartan in patients with hypertension and renal insufficiency [abstract no. E025]Am J Hypertens, 11
-
A. Zanchetti, J. Chalmers, K. Arakawa, I. Gyárfás, P. Hamet, L. Hansson, S. Julius, S. MacMahon, G. Mancia, J. Ménard, T. Omae, J. Reid, M. Safar (1993)
1993 Guidelines for the Management of Mild Hypertension: Memorandum From a World Health Organization/ International Society of Hypertension MeetingHypertension, 22
-
P. Howe, P. Phillips, R. Saini, K. Kassler-Taub (1999)
The Antihypertensive Efficacy of the Combination of Irbesartan and Hydrochlorotfflazide Assessed by 24-Hour Ambulatory Blood Pressure MonitoringClinical and Experimental Hypertension, 21
-
T. Gress, F. Nieto, E. Shahar, M. Wofford, F. Brancati (2000)
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitusThe New England Journal of Medicine, 342
-
F. Ziai, M. Ots, A. Provoost, J. Troy, H. Rennke, B. Brenner, H. Mackenzie (1996)
The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.Kidney international. Supplement, 57
-
W. Birkenhäger, P. Leeuw (1999)
Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.Journal of hypertension, 17 7
-
T Kahan, K Malmqvist, M Edner (1998)
Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbesartan and beta-blockade [abstract no. 857-4]J Am Coll Cardiol, 31
-
M. Stearne, S. Palmer, M. Hammersley, S. Franklin, R. Spivey, J. Levy, C. Tidy, N. Bell, J. Steemson, B. Barrow, R. Coster, K. Waring, L. Nolan, E. Truscott, N. Walravens, B. Cook, H. Lampard, C. Merle, P. Parker, J. Mcvittie, I. Draisey, L. Murchison, A. Brunt, M. Williams, D. Pearson, X. Petrie, M. Lean, D. Walmsley, F. Lyall, E. Christie, J. Church, E. Thomson, A. Farrow, J. Stowers, M. Stowers, K. McHardy, N. Patterson, A. Wright, N. Levi, A. Shearer, R. Thompson, G. Taylor, S. Rayton, M. Bradbury, A. Glover, A. Smyth-Osbourne, C. Parkes, J. Graham, P. England, S. Gyde, C. Eagle, B. Chakrabarti, J. Smith, J. Sherwell, E. Kohner, A. Dornhorst, M. Doddridge, M. Dumskyj, S. Walji, P. Sharp, M. Sleightholm, G. Vanterpool, C. Rose, G. Frost, M. Roseblade, S. Elliott, S. Forrester, M. Foster, K. Myers, R. Chapman, J. Hayes, T. Henry, M. Featherston, G. Archbold, M. Copeland, R. Harper, I. Richardson, S. Martín, H. Davison, D. Hadden, L. Kennedy, A. Atkinson, A. Culbert, C. Hegan, H. Tennet, N. Webb, I. Robinson, J. Holmes, P. Bell, D. McCance, J. Rutherford, S. Nesbitt, A. Spathis, S. Hyer, M. Nanson, J. James, J. Tyrell, C. Davis, P. Strugnell, M. Booth, H. Petrie, D. Clark, B. Rice, S. Hulland, J. Barron, J. Yudkin, B. Gould, J. Singer, A. Badenock, M. Eckert, K. Alibhai, E. Marriot, C. Cox, R. Price, M. Fernandez, A. Ryle, S. Clarke, G. Wallace, E. Mehmed, S. Macfarlane, R. Greenwood, J. Wilson, M. Denholm, R. Temple, K. Whitfield, F. Johnson, C. Munroe, S. Gorick, E. Duckworth, M. Flatman, S. Rainbow, L. Borthwick, D. Wheatcroft, R. Seaman, R. Christie, W. Wheatcroft, P. Musk, J. White, S. McDougal, M. Bond, P. Raniga, R. Newton, R. Jung, C. Roxburgh, B. Kilgallon, L. Dick, N. Waugh, S. Kilby, A. Ellingford, J. Burns, C. Fox, M. Holloway, H. Coghill, N. Hein, A. Fox, W. Cowan, M. Richard, K. Quested, S. Evans, R. Paisey, N. Brown, A. Tucker, R. Paisey, F. Garrett, J. Hogg, P. Park, K. Williams, Philip Harvey, R. Wilcocks, S. Mason, J. Frost, C. Warren, P. Rocket, L. Bower, J. Roland, D. Brown, J. Youens, K. Stanton-King, H. Mungall, W. Maddison, D. Donnelly, S. King, P. Griffin, S. Smith, S. Church, G. Dunn, Andrew Wilson, K. Palmer, P. Brown, D. Humphriss, A. Davidson, R. Rose, L. Armistead, S. Townsend, P. Poon, I. Peacock, N. Culverwell, M. Charlton, B. Connolly, J. Peacock, J. Barrett, J. Wain, W. Beeston, G. King, P. Hill, A. Boulton, A. Robertson, Katoulis, A. Olukoga, H. McDonald, S. Kumar, F. Abouaesha, B. Abuaisha, E. Knowles, S. Higgins, J. Booker, J. Sunter, K. Breislin, R. Parker, P. Raval, J. Curwell, H. Davenport, G. Shawcross, A. Prest, J. Grey, H. Cole, C. Sereviratne, R. Young, T. Dornan, J. Clyne, M. Gibson, I. O'Connell, L. Wong, S. Wilson, K. Wright, C. Wallace, D. McDowell, A. Burden, E. Sellén, R. Gregory, M. Roshan, N. Vaghela, M. Burden, C. Sherriff, J. Clarke, J. Grenfell, J. Tooke, K. Macleod, C. Searnark, M. Rammell, C. Pym, J. Stockman, C. Yeo, J. Piper, L. Leighton, E. Green, M. Hoyle, K. Jones, A. Hudson, A. James, A. Shore, A. Higham, B. Martin (1998)
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39BMJ, 317
-
M. Burnier, Michael Hagman, J. Nussberger, J. Biollaz, Catherine Armagnac, R. Brouard, B. Waeber, Hans Brunner (1995)
Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects.Hypertension, 25 4 Pt 1
-
R. Turner, R. Holman (1998)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.BMJ
-
C. Cazaubon, J. Gougat, F. Bousquet, P. Guiraudou, R. Gayraud, C. Lacour, A. Roccon, G. Galindo, G. Barthelemy, B. Gautret (1993)
Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist.The Journal of pharmacology and experimental therapeutics, 265 2
-
S Villatico Campbell, V Rizzo, F Maio (1999)
Comparison of irbesartan versus enalapril on left ventricular mass and function in stage I–II hypertensives [abstract no. P.70]J Hum Hypertens, 13
-
M Escolar, A López Ocariz, M Simón (1998)
Effects of antacids on irbesartan pharmacokinetics [abstract no. FC-8]Methods Find Exp Clin Pharmacol, 20
-
R. Fogari, S. Ambrosoli, L. Corradi, E. Esposti, L. Mos, R. Nami, F. Nicrosini, A. Pessina, A. Salvetti, A. Vaccarella, A. Zanchetti, A. Martín, R. Reeves (1997)
24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' Group.Journal of hypertension, 15 12 Pt 1
-
M Pohl, M Cooper, J Ulrey (1997)
Safety and efficacy of irbesarten in hypertensive patients with type II diabetes and proteinuria [abstract no. D4]Am J Hypertens, 10
-
G. Mancia, M. Stella, G. Grassi (1999)
New drugs for the treatment of hypertension.Current opinion in cardiology, 14 5
-
T LeJemtel, N Awan, C-s Liang (1996)
Irbesartan - a new angiotensin II antagonist: acute hemodynamic effects in patients with heart failure [abstract no3646]. Circulation, 1
-
J. Pool, R. Guthrie, T. Littlejohn, P. Raskin, Alexander Shephard, Michael Weber, M. Weir, T. Wilson, James Wright, K. Kassler-Taub, R. Reeves (1998)
Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.American journal of hypertension, 11 4 Pt 1
-
R. Fogari, A. Zoppi, A. Mugellini, P. Preti, L. Corradi, P. Lusardi (1999)
Effect of Low-Dose Manidipine on Ambulatory Blood Pressure in Very Elderly HypertensivesCardiovascular Drugs and Therapy, 13
-
X. Xi, K. Graf, S. Goetze, E. Fleck, W. Hsueh, R. Law (1999)
Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells.Arteriosclerosis, thrombosis, and vascular biology, 19 1
-
JJ McNeil, H Kram (1997)
Avery’s drag treatment -
K. Kassler-Taub, T. Littlejohn, W. Elliott, T. Ruddy, Evelyn Adler (1998)
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.American journal of hypertension, 11 4 Pt 1
-
LG Tan, DS Chang, LF Lukman (1999)
Irbesartan decreases atrial natriuretic peptide levels and improves ejection fraction in diabetic patients with congestive heart failure [abstract]Cardiovasc Drugs Ther, 13
-
C Lacour, F Canals, C Cazaubon (1995)
Central effects of irbesartan, an AT1 antagonist in rats [abstract]Pharmacol Res, 31
-
M. Cooper, D. Anzalone, L. Townes, C. Masson, V. Mareyev, E. Esposti, A. Jaina, G. Maschio (1998)
E025: Safety and efficacy of irbesartan in patients with hypertension and renal insufficiencyAmerican Journal of Hypertension, 11
-
R. Reeves, Chen-Sheng Lin, K. Kassler-Taub, H. Pouleur (1998)
Dose-related efficacy of irbesartan for hypertension: an integrated analysis.Hypertension, 31 6
-
TN Thrasher, CP Shifflett, DJ Ramsay (1999)
Blockade of angiotensin type 1 (AT1) receptors reduces ventricular hypertrophy in response to aortic stenosis in rats [abstract no. F002]Am J Hypertens, 12
-
M. Marino, K. Langenbacher, N. Ford, R. Raymond, J. Manning, O. Vesterqvist, E. Shamblen, K. Lasseter (1999)
Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate HypertensionJournal of Cardiovascular Pharmacology and Therapeutics, 4
-
H. Tan, Charles Hou, R. Sung (1999)
Effects of Adenosine A1-receptor activation on Torsade de Pointes in RabbitsCardiovascular Drugs and Therapy, 13
-
P. Vanderheyden, F. Fierens, J. Backer, G. Vauquelin (2000)
Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors.Biochemical pharmacology, 59 8
-
AV Chobanian (1998)
Comparison of the effects of ACE inhibition and AT1 receptor blockade on atherosclerosis [abstract]Am J Hypertens, 11
-
M Tonkon, N Awan, I Niazi (2000)
A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failureInt J Clin Pract, 54
-
J. Culman, Christian Heyer, Britta Piepenburg, W. Rascher, T. Unger (1999)
Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.European journal of pharmacology, 367 2-3
-
L. Ruilope (1997)
Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 15 7
-
F. Fierens, P. Vanderheyden, J. Backer, G. Vauquelin (1999)
Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.European journal of pharmacology, 372 2
-
R. Collins, R. Peto, S. MacMahon, P. Hebert, N. Fiebach, K. Eberlein, Jon Godwin, N. Qizilbash, JamesO Taylor, C. Hennekens (1990)
Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological contextThe Lancet, 335
-
A. Cohen, B. Bregman, E. Rosei, Bryan Williams, O. Dubourg, P. Clairefond, P. Brudi, Philippe Gosse, P. Guéret (1998)
Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (The SILVER trial)Journal of Human Hypertension, 12
-
M. Tonkon, N. Awan, I. Niazi, P. Hanley, L. Baruch, R. Wolf, A. Block (2000)
A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group.International journal of clinical practice, 54 1
- Publisher
- Springer Journals
- Copyright
- Copyright © 2000 by Adis International Limited
- Subject
- Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
- ISSN
- 0012-6667
- eISSN
- 1179-1950
- DOI
- 10.2165/00003495-200059050-00014
- pmid
- 10852648
- Publisher site
- See Article on Publisher Site
Abstract
Drugs 2000 May; 59 (5): 1187-1206 ADIS DRUG EVALUATION 0012-6667/00/0005-1187/$25.00/0 © Adis International Limited. All rights reserved. An Updated Review of its Use in Cardiovascular Disorders Anthony Markham, Caroline M. Spencer and Blair Jarvis Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: V. Bonarjee, Division of Cardiology, Department of Medicine, Central Hospital in Rogaland, Stavanger, Norway; M. Burnier, Policlinique Médicale Universitaire, Lausanne, Switzerland; S.G. Carruthers, Department of Medicine, Faculty of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada; E. Havranek, Department of Medicine/Cardiology Division; Denver Health Medicine Center, Denver, Colorado, USA; L. Ruilope, Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain; P. Vanderheyden, Department of Molecular Pharmacology, Free University of Brussels, Brussels, Belgium. Data Selection Sources: Medical literature published in any language since 1997 on Irbesartan, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International, Auckland, New Zealand). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘Irbesartan’ or ‘BMS 186295’ or ‘SR 47436’. EMBASE search terms were ‘Irbesartan’ or ‘BMS 186295’ or
Journal
Drugs – Springer Journals
Published: Oct 10, 2012